Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Electrophysiological Characterization of Inducible Pluripotent Stem Cell–Derived Human β-Like Cells and an SLC30A8 Disease Model

Manon Jaffredo, Nicole A.J. Krentz, Benoite Champon, Claire E. Duff, Sameena Nawaz, Nicola Beer, Christian Honore, Anne Clark, Patrik Rorsman, Jochen Lang, Anna L. Gloyn, Matthieu Raoux, Benoit Hastoy

Diabetes 2024;73(8):1255–1265

https://doi.org/10.2337/db23-0776

Published: 22 May 2024

View article titled, Electrophysiological Characterization of Inducible Pluripotent Stem Cell–Derived Human β-Like Cells and an <em>SLC30A8</em> Disease Model

Meeting Abstracts

773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

FRANCESCO GIORGINO, CRISTIAN GUJA, MELANIE J. DAVIES, HASAN AYDIN, FELIPE LAUAND, ELISABETH SOUHAMI, LYDIE MELAS-MELT, VANITA R. ARODA, JULIO ROSENSTOCK

Diabetes 2023;72(Supplement_1):773-P

https://doi.org/10.2337/db23-773-P

Published: 20 June 2023

View article titled, 773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

Meeting Abstracts

271-OR: Capillary Blood Ketone Level and Future Ketoacidosis Risk in Type 1 Diabetes Using Sodium–Glucose Linked Transporter Inhibitors

PRIYA BAPAT, SHARON DHALIWAL, CIMON SONG, DALTON R. BUDHRAM, ABDULMOHSEN M.K. BAKHSH, DANIEL SCARR, ALANNA WEISMAN, MICHAEL FRALICK, NOAH IVERS, DAVID CHERNEY, DOUG MUMFORD, GEORGE TOMLINSON, LEIF ERIK LOVBLOM, BRUCE A. PERKINS

Diabetes 2023;72(Supplement_1):271-OR

https://doi.org/10.2337/db23-271-OR

Published: 20 June 2023

View article titled, 271-OR: Capillary Blood Ketone Level and Future Ketoacidosis Risk in Type 1 Diabetes Using Sodium–Glucose Linked Transporter Inhibitors

Meeting Abstracts

125-OR: Disparities in Access to Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i)

DONGLAN S. ZHANG, ANAND RAJAN, SHAHIDUL ISLAM, DAVID M. CHARYTAN, ALAN M. JACOBSON, JASMIN DIVERS

Diabetes 2023;72(Supplement_1):125-OR

https://doi.org/10.2337/db23-125-OR

Published: 20 June 2023

View article titled, 125-OR: Disparities in Access to Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i)

Meeting Abstracts

880-P: Effects of Sodium–Glucose Cotransporter-2 Inhibitors on the Risk of Atrial Fibrillation in Older Adults with Type 2 Diabetes

YUJIA LI, YI GUO, STEPHEN KIMMEL, JIANG BIAN, DESMOND SCHATZ, JINGCHUAN GUO

Diabetes 2023;72(Supplement_1):880-P

https://doi.org/10.2337/db23-880-P

Published: 20 June 2023

View article titled, 880-P: Effects of Sodium–Glucose Cotransporter-2 Inhibitors on the Risk of Atrial Fibrillation in Older Adults with Type 2 Diabetes

Meeting Abstracts

7-LB: Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i) Decrease Kidney Oxygen Consumption in Adults with Type 2 Diabetes (T2D)—A Randomized Clinical Trial Using 11C-Acetate Positron Emission Tomography (PET) Imaging

ANNE HESP, LARS I.P. SNEL, PATRICK SCHOBER, LOTHAR A. SCHWARTE, RONALD BOELLAARD, PETTER BJORNSTAD, DANIËL VAN RAALTE

Diabetes 2023;72(Supplement_1):7-LB

https://doi.org/10.2337/db23-7-LB

Published: 20 June 2023

View article titled, 7-LB: Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i) Decrease Kidney Oxygen Consumption in Adults with Type 2 Diabetes (T2D)—A Randomized Clinical Trial Using 11C-Acetate Positron Emission Tomography (PET) Imaging

Meeting Abstracts

875-P: Association of Continued Sodium–Glucose Cotransporter-2 Inhibitors from the Ambulatory to Inpatient Setting with In-Hospital Outcomes in Patients with Diabetes Mellitus—A Nationwide Study

LAKSHMI G. SINGH, SPYRIDON NTELIS, TARIQ SIDDIQUI, STEPHEN L. SELIGER, JOHN D. SORKIN, ILIAS (ELIAS) SPANAKIS

Diabetes 2023;72(Supplement_1):875-P

https://doi.org/10.2337/db23-875-P

Published: 20 June 2023

View article titled, 875-P: Association of Continued Sodium–Glucose Cotransporter-2 Inhibitors from the Ambulatory to Inpatient Setting with In-Hospital Outcomes in Patients with Diabetes Mellitus—A Nationwide Study

Meeting Abstracts

396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes

ELISABETH BUUR STOUGAARD, PETER L. KRISTENSEN, URD KIELGAST, SR., HENRIK U. ANDERSEN, YASMIN H. HAMID, PETER GÆDE, ESBEN SØNDERGAARD, GRY DØRFLINGER, KAREN K. FJELDBORG, KLAVS W. HANSEN, HENRIK H. THOMSEN, THURAYA AL-IMARI, MICHAEL RØDER, PETER ROSSING, FREDERIK PERSSON

Diabetes 2022;71(Supplement_1):396-P

https://doi.org/10.2337/db22-396-P

Published: 01 June 2022

View article titled, 396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes

Meeting Abstracts

177-OR: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Incident Atrial Fibrillation in Older Adults with Type 2 Diabetes

MIN ZHUO, JULIE M. PAIK, DEBORAH J. WEXLER, BRENDAN M. EVERETT, ELVIRA D'ANDREA, ROBERT GLYNN, SEOYOUNG C. KIM, ELISABETTA PATORNO

Diabetes 2022;71(Supplement_1):177-OR

https://doi.org/10.2337/db22-177-OR

Published: 01 June 2022

View article titled, 177-OR: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Incident Atrial Fibrillation in Older Adults with Type 2 Diabetes

Meeting Abstracts

182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series

HENRIK MAAGENSEN, SOFIE HAEDERSDAL, JESPER KROGH, TORBEN HANSEN, FILIP K. KNOP, TINA VILSBØLL

Diabetes 2022;71(Supplement_1):182-OR

https://doi.org/10.2337/db22-182-OR

Published: 01 June 2022

View article titled, 182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series

Meeting Abstracts

799-P: Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Atrial Fibrillation among Patients with Type 2 Diabetes

SEUNG EUN LEE, YOO RI KIM, HYEWON NAM, HOSEOB KIM, JAEHWAN KIM, KYOUNG-AH KIM

Diabetes 2021;70(Supplement_1):799-P

https://doi.org/10.2337/db21-799-P

Published: 01 June 2021

View article titled, 799-P: Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Atrial Fibrillation among Patients with Type 2 Diabetes

Meeting Abstracts

353-P: Safety and Tolerability of Sodium-Glucose Cotransporter 2 Inhibitors during Ramadan Fasting

ELSAYED M.A. EID, ABDELAZIZ HUSSEIN, HOSSAM A. GHAZI

Diabetes 2021;70(Supplement_1):353-P

https://doi.org/10.2337/db21-353-P

Published: 01 June 2021

View article titled, 353-P: Safety and Tolerability of Sodium-Glucose Cotransporter 2 Inhibitors during Ramadan Fasting

Meeting Abstracts

1153-P: Sodium-Glucose Cotransporter-2 Inhibitors Increase Food Intake via a Mechanism That Acts on the Central Nervous System Involving Phosphorylation of Adenosine Monophosphate-Activated Protein Kinase in the Lateral Hypothalamus

KENJI TAKEDA, HIRAKU ONO, TOMOHIRO OHNO, KOUTARO YOKOTE

Diabetes 2021;70(Supplement_1):1153-P

https://doi.org/10.2337/db21-1153-P

Published: 01 June 2021

View article titled, 1153-P: Sodium-Glucose Cotransporter-2 Inhibitors Increase Food Intake via a Mechanism That Acts on the Central Nervous System Involving Phosphorylation of Adenosine Monophosphate-Activated Protein Kinase in the Lateral Hypothalamus

Meeting Abstracts

1093-P: Incidence of Primary Nonadherence to Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Agonists (GLP-1A) in an Integrated Health Care System

JING LUO, ROBERT FELDMAN, SCOTT D. ROTHENBERGER, MICHAEL FISCHER, MARY T. KORYTKOWSKI, WALID F. GELLAD

Diabetes 2021;70(Supplement_1):1093-P

https://doi.org/10.2337/db21-1093-P

Published: 01 June 2021

View article titled, 1093-P: Incidence of Primary Nonadherence to Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Agonists (GLP-1A) in an Integrated Health Care System

Meeting Abstracts

128-LB: Sodium–Glucose Cotransporter-2 Inhibitors and Risk of Retinal Vein Occlusion among Patients with Type 2 Diabetes: A Propensity Score–Matched Cohort Study

MIN-KYUNG LEE, KYUNGDO HAN, HYUK-SANG KWON, YOUNG-JUNG ROH

Diabetes 2021;70(Supplement_1):128-LB

https://doi.org/10.2337/db21-128-LB

Published: 01 June 2021

View article titled, 128-LB: Sodium–Glucose Cotransporter-2 Inhibitors and Risk of Retinal Vein Occlusion among Patients with Type 2 Diabetes: A Propensity Score–Matched Cohort Study

Meeting Abstracts

421-P: Efficacy and Safety of Sodium–Glucose Cotransporter-2 Inhibitors: A Systematic Review and Meta-analysis

JASON ALEXANDER, ERIN M. STAAB, WEN WAN, MELISSA FRANCO, ALEXANDRA C. KNITTER, CELESTE C. THOMAS, VALERIE G. PRESS, MELTEM ZEYTINOGLU, REZA SKANDARI, KATHRYN E. GUNTER, BRITTANY BINDON, SANJAY JUMANI, SHARI D. BOLEN, NISA M. MARUTHUR, ELBERT HUANG, LOUIS H. PHILIPSON, NEDA LAITEERAPONG

Diabetes 2020;69(Supplement_1):421-P

https://doi.org/10.2337/db20-421-P

Published: 01 June 2020

View article titled, 421-P: Efficacy and Safety of Sodium–Glucose Cotransporter-2 Inhibitors: A Systematic Review and Meta-analysis

Meeting Abstracts

88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting

JULIO ROSENSTOCK, AMAR ALI, JURIS J. MEIER, FRANCESCO GIORGINO, CRISTIAN GUJA, MARTIN PRAZNY, ROBERT LUBWAMA, ELISABETH SOUHAMI, LAWRENCE BLONDE

Diabetes 2020;69(Supplement_1):88-LB

https://doi.org/10.2337/db20-88-LB

Published: 01 June 2020

View article titled, 88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting

Meeting Abstracts

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

YOSHIRO FUSHIMI, ATSUSHI OBATA, JUNPEI SANADA, YUKA NOGAMI, TOMOKO IKEDA, YOSHIYUKI OBATA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2020;69(Supplement_1):2054-P

https://doi.org/10.2337/db20-2054-P

Published: 01 June 2020

View article titled, 2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

Meeting Abstracts

138-LB: First-in-Human Study of YG1699, an SGLT1 and SGLT2 Dual Transporter Inhibitor

CHENGHAI LI, TONG LI, FRANK LEE, ROGER H. XU, HELEN WANG

Diabetes 2020;69(Supplement_1):138-LB

https://doi.org/10.2337/db20-138-LB

Published: 01 June 2020

View article titled, 138-LB: First-in-Human Study of YG1699, an SGLT1 and SGLT2 Dual Transporter Inhibitor

Meeting Abstracts

7-OR: Effect of Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on Vascular Function in Patients with Type 2 Diabetes Compared with Gliclazide

SOO LIM, DAVID CHERNEY

Diabetes 2019;68(Supplement_1):7-OR

https://doi.org/10.2337/db19-7-OR

Published: 01 June 2019

View article titled, 7-OR: Effect of Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on Vascular Function in Patients with Type 2 Diabetes Compared with Gliclazide

NARROW

Electrophysiological Characterization of Inducible Pluripotent Stem Cell–Derived Human β-Like Cells and an SLC30A8 Disease Model

773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

271-OR: Capillary Blood Ketone Level and Future Ketoacidosis Risk in Type 1 Diabetes Using Sodium–Glucose Linked Transporter Inhibitors

125-OR: Disparities in Access to Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i)

880-P: Effects of Sodium–Glucose Cotransporter-2 Inhibitors on the Risk of Atrial Fibrillation in Older Adults with Type 2 Diabetes

7-LB: Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i) Decrease Kidney Oxygen Consumption in Adults with Type 2 Diabetes (T2D)—A Randomized Clinical Trial Using 11C-Acetate Positron Emission Tomography (PET) Imaging

875-P: Association of Continued Sodium–Glucose Cotransporter-2 Inhibitors from the Ambulatory to Inpatient Setting with In-Hospital Outcomes in Patients with Diabetes Mellitus—A Nationwide Study

396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes

177-OR: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Incident Atrial Fibrillation in Older Adults with Type 2 Diabetes

182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series

799-P: Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Atrial Fibrillation among Patients with Type 2 Diabetes

353-P: Safety and Tolerability of Sodium-Glucose Cotransporter 2 Inhibitors during Ramadan Fasting

1153-P: Sodium-Glucose Cotransporter-2 Inhibitors Increase Food Intake via a Mechanism That Acts on the Central Nervous System Involving Phosphorylation of Adenosine Monophosphate-Activated Protein Kinase in the Lateral Hypothalamus

1093-P: Incidence of Primary Nonadherence to Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Agonists (GLP-1A) in an Integrated Health Care System

128-LB: Sodium–Glucose Cotransporter-2 Inhibitors and Risk of Retinal Vein Occlusion among Patients with Type 2 Diabetes: A Propensity Score–Matched Cohort Study

421-P: Efficacy and Safety of Sodium–Glucose Cotransporter-2 Inhibitors: A Systematic Review and Meta-analysis

88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

138-LB: First-in-Human Study of YG1699, an SGLT1 and SGLT2 Dual Transporter Inhibitor

7-OR: Effect of Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on Vascular Function in Patients with Type 2 Diabetes Compared with Gliclazide

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only